当前位置: X-MOL 学术Prostate › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients
The Prostate ( IF 2.6 ) Pub Date : 2021-09-15 , DOI: 10.1002/pros.24235
Benedikt Hoeh 1, 2 , Christoph Würnschimmel 2, 3 , Rocco S Flammia 2, 4 , Benedikt Horlemann 2 , Gabriele Sorce 2, 5 , Francesco Chierigo 2, 6 , Zhe Tian 2 , Fred Saad 2 , Markus Graefen 3 , Michele Gallucci 4 , Alberto Briganti 5 , Carlo Terrone 6 , Shahrokh F Shariat 7, 8, 9, 10, 11, 12 , Derya Tilki 3, 13 , Luis A Kluth 1 , Philipp Mandel 1 , Felix K H Chun 1 , Pierre I Karakiewicz 2
Affiliation  

Over the last decade, multiple clinical trials demonstrated improved survival after chemotherapy for metastatic prostate cancer (mPCa). However, real-world data validating this effect within large-scale epidemiological data sets are scarce. We addressed this void.

中文翻译:

改善当代转移性前列腺癌化疗暴露患者的总体和癌症特异性生存率

在过去十年中,多项临床试验表明,转移性前列腺癌 (mPCa) 化疗后生存率有所提高。然而,在大规模流行病学数据集中验证这种效应的真实数据很少。我们解决了这个空白。
更新日期:2021-11-03
down
wechat
bug